Member Info for Quickdraw18

Picathartes this post got deleted from Avacta board. So thanks for sharing over here, I'll repost it

Remix, keeping it fresh

https://open.spotify.com/track/05KtesHjQKdnL2NDryCZ4d?si=hAZb0_AaTWCywQVmhJFdeg&utm_source=copy-link

Zoom0001 what's wrong?

Having most of UK print media pumping fake news to pump price isn't good enough for you. So you get scared by one correct idiot like me?

Folk can beg all they like, I'll do what i want and will have fun at the same time

Though shant be bothered by BB posters,
Though shall so what's right
Though shall back NCYT
Though shall call out crap

Hahah Chris :-)

Choose NovaTalk on Friday at 1pm to hear from Prof Sharon Pea**** of Cambridge uni talk about the UK's and Novacyt's effort in screening for variants, sequencing and why the Professor thinks COVID sequencing will persist for 10 yrs

https://twitter.com/PrimerdesignLtd/status/1362829598841569283?s=19

Choose listening to Dr Jonathan Sackier where he discusses the role of #diagnostic tests and #sequencing in the management of a global pandemic with our highly respected group of panellists

https://t.co/8lblaG3IG1 #Novacyt #NCYT #COVID19 https://t.co/nwE9QDtOne
https://twitter.com/PrimerdesignLtd/status/1363188510413447174?s=19

Choose facts not grandeur and empty generic sound bites

Buy British, buy UK, buy PCR, buy Novacyt, buy SNPsig.....

As said back to Novacyt. Hopefully there no need for inferred commentary about LFT's. I've proven my point

The lesson for you is don't bang on about LFT's and your avacta investment on here.

Van v we were chatting last night

Terrible news for Avacta . It wasn't the saliva test that failed UK gov testing but it's nasal test. The saliva test had already been pulled. Now their second attempt a nasal test has failed UK validation.

I'll now redirect my energy to Novacyt and PCR, probably best that LFT's and Avacta stays off this board. Of course I'm not above gloating.

And guess what, here's the joke

"The press report this weekend incorrectly stated that a saliva-based rapid antigen test from Avacta had been evaluated at Porton Down. In fact, the evaluated test was the anterior nasal swab test that has subsequently generated the excellent initial clinical performance data outlined above. However, in its evaluation Porton Down used artificial samples and did not use clinical samples"

"While Avacta continues to be in dialogue with the DHSC, and with other organisations in the UK and abroad, with a view to future supply of its rapid antigen test, it is prioritising the full clinical validation of its nasal swab-based SARS-CoV-2 rapid antigen test as a pre-requisite for CE marking and broad commercialisation"

You posted this on the back of me sharing my project plan from September. A plan which looks me the most accurate plan of Avacta timeline I've seen on this forum or from the company.
For those without the time to look back, September 10th suggested to Rich Ken commercial sales would happen around Feb/March.

Rather than acknowledge my post you thought it was appropriate to post the following:

"Quickdraw18 - as I've said, the provider of the SLFT is irrelevant from an NCYT perspective. Obviously, I do not know if you are aware of the updated article from the Huffington Post, presumably you are not because I'm sure you would have presented the full picture had you been aware of this:

'A previous version of the Avacta test, which relied on saliva rather than nasal swabs, did not pass testing by Porton Down last month. However, the latest updated version has shown excellent preliminary results and is currently being assessed

I'm sure you will agree that completeness and accuracy often go hand-in-hand"

I've since let you and the board in on a fraction of what i know of Avacta. So while you can choose to deflect and distract my fact file and knowledge base is going no where.

PS
I'm saving my jokes for the right moment

lol we don't all have messiah sizes egos. This is a bb not a popularity contest. Folks and hate on me all day long. Not an issue.

I'll judge myself on the accuracy of my predictions.

So when do you see the self approved CE mark being awarded and on sale for research purposes?

And whens will UK clinical validation arrive and sales for clinical use?

PS were you for telling yesterday that Avacta's saliva LFT had failed Porton Down validation?

Night, night all.

I'll check in on you tomorrow V

I said I would not pre judge a clinical trail outcome, but based on past performance Zika, COVID saliva LFT the probability doesn't look great.

The company are aiming for CE self approval via Mologic "around the end of this quarter" AS Avacta. I don't see outcome of UK Gov clinical trails for at least 2 months after CE approval, say end May.

As its question time when do you estimate Avacta will have a LFT test available for research purposes and for clinical use?

And your right I don't use this board for humour. Research, sharing info and the occasional passive aggressiveness when someone tries to talk down to me

Want happened to Zika test, annouced in 2016, mentioned in 2017. Vanished without a trace

And once again don't try and insult me again van v.

. No mention first 13 yrs of failed business model on in Key Investor page or their origination as animal bio company in 1999. Page says they came to AIM in 2006.

. 2012 purchased Affimers, then focused on reagents, then tests and therapy.

. 2018 purchased pre|CISION for blood toxicity conditioning.

. Main two arms of business Affimers and pre|CISION were bought in.

https://avacta.com/investors/key-information

. July 01 - Dale MUSGROVE (2) 1.5 yrs
. July 01 - Mark Alister VAREY (4) 2 yrs
. Sep 02 - Allan CHARLESWOTH (4)
1 yr
. Sep 2003 - Norman MOLYNEUX (49) 5 months
. Dec 04 - Peter David George COUSINS (2) 2.5 yrs
. July 2005 - Brian Paul BENNETT
. July 2006 - Colin Ernest DAVIES
. July 2006 - Keith William SALISBURY
. Apr 2006 - Kui Man YEUNG
. Aug 2006 - Daron LEE
. Aug 2006 - Mark Anthony SHIELDS
. Mar 07 - Andrew James NAYLOR (2) 3 yrs
. Sep 2007 - Alan Arthur BRAIN (2)
. June 07 - Gillian Ruth HART (2) 2 yrs
. Dec 2007 - Michael John BAILEY
. Dec 2007 - Graham HAN**** (2) 2.5 yrs
. Dec 07 - John GRAHAM (8) 8 yrs
. Dec 08 - Roy Stafford JOHNSON (5) - 4 yrs
. Jan 09 - Richard Edward Winter HALLIWELL (6) 7 yrs
. Jan 09 - Beverley Clare HARRISON (13) 8.5 yrs
. Jan 2011 - Gwynfor Owen HUMPHREYS
. March 2011 - Kurt Justin BALDWIN (3)
. Match 2011 - Christopher Robert DRYDEN (1) 39 months
. March 2011 - Russell HODGETTS
. March 2011 - Barry PORTER
. March 2011 - Simon WEBSTER
. Nov 2011 - Anthony William ROBARDS
. Jan 12 - Michael Alexander DALRYMPLE (2) 22 months
. Jan 12 - Terence Howard RABBITTS (4) 21 months
. Dec 15 - Timothy James SYKES (96) 8.5 yrs
. Jan 2016 - Anthony William ROBARDS (25) 4 yrs 3 months
. Jan 17 - Paul KO FERRIGNO (1) 9 yrs
. March 17 - Janice Elaine HOGG (7) 16 yrs
. Dec 17 - Richard Craig Alan SLATER (70) 3)

Which phase Phase 2 UK validation (71 negative samples, 60 spiked positive samples) or Phase 3 UK Clinical validation (1,000 negative samples, 200 spiked positive samples)?

It's your posts devoid meaningful COVID knowledge, yet full of grandeur that I humour.

I won't choose to presume the outcome of a clinical trail. The Innova test passed UK. Clinical trails and the Avacta initial data was very close to the Innova data once you take out the clever use of reporting the data at a CT of <26

What I will say is when a company has a history of failed projects dating back to 1998 l, with a revolving door of directors (34 exits since 2001) I'll go with past performance and expect this phase of the company to be as successful as its prior years

If we had a straight shooting government I'd say no contact and no LFT. But with this government maybe go save face they get at some point a non binding contact to produce a test.

The Abbott LFT is available to buy in the UK for £35 today. See my tweet for my comparison of the Abbot test with Innova test. Not amazing but in a pandemic whey wait many more months if these LFT's are so critical.

No need to wait for:
. final manufacturing ramp up
. Phase 2 clinical validation
(Avacta's relatively small initial clinical validation used 30 positive and 26 negative samples)

Phase 2 UK validation :
(71 negative samples, 60 spiked postive samples)

Phase 3 UK Clinical validation
(1,000 negative samples, 200 spiked postive samples)

https://twitter.com/DopeinkInvest/status/1363253896685236224?s=19

One more thing Van V you may post more on here, but do yourself a favour and don't try and patronise me again.

I humour you and that is all

For reference all my timeline until just now has only been seen by two people and was sent on the 10th September. At the time i assumed the sample type was saliva and the manufacturer was Cytiva.
I suggested 1st sales in Feb/March. The other person Rich Ken said October hohoho.

Now please remember this is no place for name calling, let's keep it civil and factual.

Must say I was disappointed I got my estimate wrong. But how was i too know Cytiva would move on, saliva sample would fail, tech transfer to final production line wouldn't have started and initial clinical evaluation would have to take place in Spain for some reason.
Add in issues with air travel due to brexit and i can forgive myslef for estimating back on September 10th that Avacta commercial sales would happen by March.

That's said I never said which year as Alastair never said which summer. I have lots of facts and am more aware than you could imagine

I'll work up a new project plan this week and will share for prosperity

. Pilot batch - end Sep
. CONDOR - 8 weeks (end Nov)
Clinical use approval - 1st December
. Some production and sales but LFT not sensitive enough for clinic - December
. Consumer / point of use approval - 3>4 months (Jan/Feb)
. 1st sales - (Feb/March)

Produced this high level LFT project plan for a saliva test back in September.

Prototype
Initial evaluation
Design Freeze
Prod on final production line
CE Mark
Available for research purposes
Clinical Validation
Manufacturing scale up
Available for clinical use
Self test study and validation
Available for individual use

. Pilot batch - end Sep
. CONDOR - 8 weeks (end Nov)
Clinical use approval - 1st December
. Some production and sales but LFT not sensitive enough for clinic - December
. Consumer / point of use approval - 3>4 months (Jan/Feb)
. 1st sales - (Feb/March)

That was assuming things went smoothly. They didn't

I shed a small tear for the LFT's. That's all for now

Stonker of a find B2HS2L

My source told me the wrong gene for E484k mutation, it's also within the S Spike protein. The mutation was also separately Idendified in the Liverpool Bristol and one of the Brazilian stains

Good image showing the 8 major strains

So to clarify the GenExpert test by Cepheid is unaffected

https://www.dailymail.co.uk/news/article-9274907/amp/Now-scientists-spot-variant-Finland-detects-new-strain.html

andrewba ProMATE is a refined extraction method and doesn't differ from our core ORF1ab target.

For reference our original 2 gene test targeted ORF1ab and S gene. I'd imagine this has now been supersede by SNPsig and variplex which is too come

Novacyt's single gene test and associated products target the ORF1ab gene.

Mutations to this gene are very unlikely to be beneficial to the virus and thus unlikely to propagate. Selection of this gene is one of the many master stokes made by Novacyt.

The that appears to be struggling to identify the Finish strain is the GenExpert test by Cepheid which targets N gene and E gene.

GenExpert test is one of the few tests approved by the WHO and UNICEF.

Within this study of 16 labs the Cepheid GenExpert test was the most popular, used in 37% of labs. Novacyt were second most popular and used in 25% of the labs involved in the study

https://www.eurosurveillance.org/content/10.2807/1560-7917.ES.2021.26.6.2002079

Thank you for the supportive comment yesterday, sorry i didn't respond, didn't get on the forum until late. As for the haters, I'd hate on naughty sells and truth benders. We'll see at the end who's the bad man